Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial - 22/08/19
Amy S. Paller, Northwestern University Feinberg School of Medicine, Chicago, IL; Andrew Blauvelt, Oregon Medical Research Center, Portland, OR; David M. Pariser, Eastern Virginia Medical School and Virginia Clinical Research Inc, Norfolk, VA; Wiley Soong, Alabama Allergy and Asthma Center, Birmingham, AL; H. Chih-ho Hong, Dr. Chih-ho Hong Medical, Inc, Surrey, BC, and Probity Medical Research, Waterloo, ON, Canada; Rick Zhang, Regeneron Pharmaceuticals, Inc, Basking Ridge, NJ; Laurent Eckert, Sanofi, Chilly-Mazarin, France; Abhijit Gadkari, Regeneron Pharmaceuticals, Inc, Tarrytown, NY; Thomas Hultsch, Sanofi Genzyme, Cambridge, MA; Ashish Bansal, Regeneron Pharmaceuticals, Inc, Tarrytown, NY
Le texte complet de cet article est disponible en PDF.| Supported by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials. gov identifier NCT03054428. Medical writing/editorial support provided by Patricia Gómez-Pérez, MD, MPH, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals. |
Vol 81 - N° 4S1
P. AB195 - octobre 2019 Retour au numéro
Article précédent
- Do-it-yourself facial and mask home remedies on YouTube: A pantry of options
- Durability of response in plaque psoriasis patients treated with certolizumab pegol: Two year data from the CIMPASI-1 and CIMPASI-2 phase 3 trials
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?